{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"41.3"}]}],"title":"Investigator assessment"},{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"4.1","upperLimit":"NA","value":"40.1"}]}],"title":"Independent radiology review"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) was defined as the interval between the first dose of study treatment and earlier date of first radiologically documented progression or death due to any cause. If the subject did not have a documented date of progression or death, PFS was censored at the date of the last adequate assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG000","title":"Adenocarcinoma of the Small Intestine (ASI)"}],"paramType":"MEDIAN","populationDescription":"ITT/Evaluable population - Primary analysis cohort.","reportingStatus":"POSTED","timeFrame":"From study treatment start date until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 92 months (cut-off date for end of study = 10-Dec-21)","title":"Progression Free Survival (PFS) in the Adenocarcinoma of the Small Intestine (ASI) Cohort","type":"SECONDARY","unitOfMeasure":"Weeks"}